SK286040B6 - Farmaceutická kompozícia obsahujúca 1-(2-naft-2-yletyl)-4-(3- trifluórmetylfenyl)-1,2,3,6-tetrahydropyridín hydrochlorid a donepezil alebo takrín - Google Patents

Farmaceutická kompozícia obsahujúca 1-(2-naft-2-yletyl)-4-(3- trifluórmetylfenyl)-1,2,3,6-tetrahydropyridín hydrochlorid a donepezil alebo takrín Download PDF

Info

Publication number
SK286040B6
SK286040B6 SK711-2000A SK7112000A SK286040B6 SK 286040 B6 SK286040 B6 SK 286040B6 SK 7112000 A SK7112000 A SK 7112000A SK 286040 B6 SK286040 B6 SK 286040B6
Authority
SK
Slovakia
Prior art keywords
pharmaceutical composition
trifluoromethylphenyl
donepezil
ylethyl
tacrine
Prior art date
Application number
SK711-2000A
Other languages
English (en)
Slovak (sk)
Other versions
SK7112000A3 (en
Inventor
Jean-Pierre Maffrand
Philippe Soubrie
Jean-Paul Terranova
Original Assignee
Sanofi - Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9714322A external-priority patent/FR2771007B1/fr
Priority claimed from FR9714324A external-priority patent/FR2771006B1/fr
Application filed by Sanofi - Aventis filed Critical Sanofi - Aventis
Publication of SK7112000A3 publication Critical patent/SK7112000A3/sk
Publication of SK286040B6 publication Critical patent/SK286040B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SK711-2000A 1997-11-14 1998-11-09 Farmaceutická kompozícia obsahujúca 1-(2-naft-2-yletyl)-4-(3- trifluórmetylfenyl)-1,2,3,6-tetrahydropyridín hydrochlorid a donepezil alebo takrín SK286040B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9714322A FR2771007B1 (fr) 1997-11-14 1997-11-14 Association de principes actifs pour le traitement de la demence senile du type alzheimer
FR9714324A FR2771006B1 (fr) 1997-11-14 1997-11-14 Association de principes actifs pour le traitement de la demence senile du type alzheimer
PCT/FR1998/002384 WO1999025363A1 (fr) 1997-11-14 1998-11-09 Association de principes actifs, notamment de tetrahydropyridines et d'agents inhibiteurs de l'acetylcholinesterase, pour le traitement de la demence senile du type alzheimer

Publications (2)

Publication Number Publication Date
SK7112000A3 SK7112000A3 (en) 2000-10-09
SK286040B6 true SK286040B6 (sk) 2008-01-07

Family

ID=26233932

Family Applications (1)

Application Number Title Priority Date Filing Date
SK711-2000A SK286040B6 (sk) 1997-11-14 1998-11-09 Farmaceutická kompozícia obsahujúca 1-(2-naft-2-yletyl)-4-(3- trifluórmetylfenyl)-1,2,3,6-tetrahydropyridín hydrochlorid a donepezil alebo takrín

Country Status (27)

Country Link
EP (1) EP1030671A1 (ko)
JP (1) JP2001523642A (ko)
KR (1) KR100599350B1 (ko)
CN (1) CN1243540C (ko)
AU (1) AU743228B2 (ko)
BG (1) BG64819B1 (ko)
BR (1) BR9814035A (ko)
CA (1) CA2309966A1 (ko)
CO (1) CO4980891A1 (ko)
DZ (1) DZ2649A1 (ko)
EA (1) EA003255B1 (ko)
EE (1) EE04235B1 (ko)
HU (1) HUP0100098A3 (ko)
ID (1) ID24933A (ko)
IL (2) IL136122A0 (ko)
IS (1) IS5482A (ko)
MY (1) MY120461A (ko)
NO (1) NO20002450L (ko)
NZ (1) NZ504420A (ko)
OA (1) OA11464A (ko)
PL (1) PL194597B1 (ko)
SA (1) SA98190747B1 (ko)
SK (1) SK286040B6 (ko)
TR (1) TR200001262T2 (ko)
TW (1) TW585766B (ko)
UY (1) UY25247A1 (ko)
WO (1) WO1999025363A1 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2389937T1 (sl) 2002-06-14 2018-10-30 Toyama Chemical Co., Ltd, Farmacevtska sestava za izboljšanje možganske funkcije
ES2327914T3 (es) * 2002-08-07 2009-11-05 Novartis Ag Metodo para pronosticar la sensibilidad al tratamiento con ravastigmina basado en el genotipo apoe de pacintes con demencia.
CN1520818A (zh) * 2003-02-09 2004-08-18 山东绿叶天然药物研究开发有限公司 治疗老年性痴呆的胆碱酯酶抑制剂药物组合物
US8481565B2 (en) 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US9796672B2 (en) 2014-01-31 2017-10-24 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
MX2019013524A (es) * 2017-05-15 2020-02-10 Cognition Therapeutics Inc Composiciones para tratar enfermedades neurodegenerativas.
KR102224918B1 (ko) 2018-03-20 2021-03-09 (주)인벤티지랩 도네페질 및 메만틴을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 복합 조성물 및 이의 제조 방법
WO2019182319A1 (ko) * 2018-03-20 2019-09-26 (주)인벤티지랩 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물의 제조 방법 및 이의 제조 방법으로 제조된 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물
CN109265391B (zh) * 2018-11-13 2021-11-19 枣庄学院 联苯多取代1,2,5,6-四氢吡啶化合物及其合成方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
US5453428A (en) * 1991-02-14 1995-09-26 The Mount Sinai School Of Medicine Of The City Of New York Method and composition for the treatment of apathy-amotivation syndrome
PL185124B1 (pl) * 1995-03-06 2003-02-28 Interneuron Pharmaceuticals Zastosowanie cytykoliny oraz jej kompozycja do wytwarzania leku przeznaczonego do ochrony tkanki mózgowej
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines

Also Published As

Publication number Publication date
DZ2649A1 (fr) 2004-12-28
IL136122A (en) 2006-07-05
EE04235B1 (et) 2004-02-16
CA2309966A1 (en) 1999-05-27
NZ504420A (en) 2003-08-29
OA11464A (en) 2003-11-18
AU1160999A (en) 1999-06-07
BR9814035A (pt) 2000-09-26
TR200001262T2 (tr) 2001-01-22
EP1030671A1 (fr) 2000-08-30
WO1999025363A1 (fr) 1999-05-27
EA200000412A1 (ru) 2000-12-25
PL194597B1 (pl) 2007-06-29
CN1285742A (zh) 2001-02-28
PL340500A1 (en) 2001-02-12
CN1243540C (zh) 2006-03-01
ID24933A (id) 2000-08-31
AU743228B2 (en) 2002-01-24
BG104428A (en) 2001-08-31
BG64819B1 (bg) 2006-05-31
KR20010032099A (ko) 2001-04-16
CO4980891A1 (es) 2000-11-27
NO20002450D0 (no) 2000-05-11
SK7112000A3 (en) 2000-10-09
EE200000290A (et) 2001-06-15
TW585766B (en) 2004-05-01
IS5482A (is) 2000-05-09
HUP0100098A3 (en) 2001-12-28
SA98190747B1 (ar) 2006-11-04
UY25247A1 (es) 2001-05-31
EA003255B1 (ru) 2003-02-27
JP2001523642A (ja) 2001-11-27
HUP0100098A2 (hu) 2001-07-30
NO20002450L (no) 2000-07-14
KR100599350B1 (ko) 2006-07-12
MY120461A (en) 2005-10-31
IL136122A0 (en) 2001-05-20

Similar Documents

Publication Publication Date Title
DE3686622T2 (de) Verwendung von dioxopiperidin-derivaten zur behandlung von anxietas, zur herabsetzung von chronischen abnormal hohen gehirn-spiegeln serotonins oder 5-hydroxy-indolessigsaeure und zur behandlung von bakteriellen oder viralen infektionen.
RU2221563C2 (ru) Фармацевтическая композиция для лечения болезни паркинсона и синдромов паркинсона, способ ее получения, способ лечения болезни паркинсона и синдромов паркинсона
MXPA02011610A (es) Combinacion de sustancia activa que contiene un opioide que tiene una estructura tipo fentanilo y cetamina.
AU2004283425A1 (en) Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
JP3468526B2 (ja) 筋萎縮性側索硬化症治療薬調製のための１−（２−ナフタ−２−イルエチル）−４−（３−トリフルオロメチルフェニル）−１，２，３，６−テトラヒドロピリジンの使用
SK286040B6 (sk) Farmaceutická kompozícia obsahujúca 1-(2-naft-2-yletyl)-4-(3- trifluórmetylfenyl)-1,2,3,6-tetrahydropyridín hydrochlorid a donepezil alebo takrín
US20050148614A1 (en) Combination of active ingredients for the treatment of senile dementia of the Alzheimer type
US6258807B1 (en) Method for treating pain
US6121291A (en) Paroxetine in the treatment of depression associated with withdrawal from heroin abuse and post-traumatic stress disorder
US6544983B2 (en) Diazepinoindoles for the treatment of chronic obstructive pulmonary disease
AU739466B2 (en) Treatment and prevention of cardiac disorders using selective serotonin re-uptake inhibitors (SSRI)
CA2559493A1 (en) Combined pharmaceutical composition for the inhibition of the decline of cognitive functions
CZ20001734A3 (cs) Farmaceutická kompozice a její použití
EP1161950A1 (en) Use of diazepinoindoles for the treatment of chronic obstructive pulmonary disease
HUT73634A (en) Use of sabeluzole for preparing pharmaceutical compositions againt chronic neurodegenerative diseases
JPS6019768A (ja) メチルレバロルフアニウム塩化合物およびその製造方法並びに薬剤
FR2771007A1 (fr) Association de principes actifs pour le traitement de la demence senile du type alzheimer